Edition:
United Kingdom

Mesoblast Ltd (MESO.OQ)

MESO.OQ on NASDAQ Stock Exchange Global Select Market

5.38USD
12 Dec 2017
Change (% chg)

$0.06 (+1.13%)
Prev Close
$5.32
Open
$5.35
Day's High
$5.43
Day's Low
$5.32
Volume
10,720
Avg. Vol
8,865
52-wk High
$12.50
52-wk Low
$4.82

Chart for

About

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced... (more)

Overall

Beta: 2.53
Market Cap(Mil.): $568.33
Shares Outstanding(Mil.): 94.09
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS

* MESOBLAST PHASE 2 TRIAL RESULTS SHOW EARLY AND DURABLE EFFECTS OF SINGLE MESENCHYMAL PRECURSOR CELL INFUSION IN BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS PATIENTS

10 Nov 2017

BRIEF-Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment

* Clinical trial of Mesoblast’S cell therapy in end-stage heart failure patients completes enrollment Source text for Eikon: Further company coverage:

28 Sep 2017

BRIEF-Mesoblast posts FY loss attributable of $76.8 mln

* FY loss attributable to owners of co $76.8 million versus loss of $4.1 million Source text for Eikon: Further company coverage:

29 Aug 2017

BRIEF-Mesoblast completes institutional entitlement offer for capital raise

* Completes institutional entitlement offer for fully underwritten A$50.7 million capital raise

29 Aug 2017

BRIEF-Mesoblast announces capital raising

* Fully underwritten accelerated non-renounceable entitlement offer to raise A$50.7m

25 Aug 2017

BRIEF-Mesoblast seeks trading halt

* Seeking trading halt pending an announcement to ASX by company regarding a fully underwritten capital raising Source text for Eikon: Further company coverage:

25 Aug 2017

BRIEF-Mesoblast Ltd files ‍​for $180 million American depositary shares representing ordinary shares

* Mesoblast Ltd - files ‍​for $180 million American depositary shares representing ordinary shares Source text: (http://bit.ly/2u50ziE) Further company coverage:

10 Jul 2017

Earnings vs. Estimates